Massachusetts General Hospital
Eric Rosenthal, MD is the director of the Massachusetts General Hospital Neurosciences Intensive Care Unit and associate professor at Harvard Medical School. As Director of Mass General Hospital’s (MGH) NeuroAI Center and core faculty in the MGH Center for Neurotechnology and NeuroRecovery, his research program has three chief pillars: 1) infrastructure to enable large-scale multicenter data science and critical care AI, 2) development and validation of computable endotypes/biomarkers in acute brain injury and status epilepticus, and 3) design and execution of clinical trials guided by brain monitoring. Dr. Rosenthal currently serves as the contact PI for the Bridge2AI CHoRUS Program, co-PI for the upcoming Ketamine for Established Status Epilepticus Treatment Trial, co-PI of the ELECTRO-BOOST EEG substudy within the BOOST-3 clinical trial, and site PI within the TRACK-TBI Network studies and in two multicenter studies focused on subarachnoid hemorrhage endotyping. In administrative roles, Dr. Rosenthal serves as a member of the Neurocritical Care Society's Guideline Committee, a member of the Curing Coma Campaign Scientific Advisory Committee, and as co-chair of the NIH Bridge2AI Consortium's Steering Committee.